Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$16.34 – $27.96
32% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.07B | $2.21B | $2.34B | $2.55B | $2.52B | $2.88B | $3.13B | $3.35B |
| Cost of revenue | $1.07B | $1.11B | $1.13B | $1.25B | $1.25B | $1.47B | $1.71B | $2.02B |
| Gross profit | $1.00B | $1.10B | $1.21B | $1.30B | $1.26B | $1.41B | $1.42B | $1.41B |
| Gross margin | 48.5% | 49.8% | 51.8% | 51.0% | 50.3% | 48.9% | 45.3% | 42.0% |
| R&D | $147.0M | $150.0M | $137.0M | $143.0M | $144.0M | $149.0M | $141.0M | $154.4M |
| Operating income | $428.0M | $486.0M | $579.0M | $582.0M | $282.0M | $367.0M | $612.0M | $580.6M |
| EBITDA | $527.0M | $584.0M | $796.3M | $705.0M | $691.0M | $791.0M | $787.0M | $797.3M |
| Net income | $282.0M | $486.0M | $431.0M | $421.0M | $188.0M | $190.0M | $359.0M | $410.9M |
| Net margin | 13.6% | 22.0% | 18.4% | 16.5% | 7.5% | 6.6% | 11.5% | 12.3% |
| EPS (diluted) | 1.17 | 2.00 | 1.81 | 1.81 | 0.84 | 0.85 | 1.61 | 1.85 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3.5B | $2.15 | $2.12–$2.20 | 1 |
| 2027 | $3.6B | $2.39 | $2.35–$2.44 | 1 |
| 2028 | $3.8B | $2.58 | $2.54–$2.64 | 2 |
| 2029 | $3.9B | $2.62 | $2.58–$2.68 | 1 |
Forward consensus · source: Financial Modeling Prep
HIKMA PHARMACEUTICALS PLC
No one on the platform currently holds HKMPF.
No tracked institution reports a position in HKMPF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-03-20 | $0.3529 | 2026-04-30 |
| 2025-08-15 | $0.2658 | 2025-09-18 |
| 2025-03-21 | $0.3721 | 2025-05-01 |
| 2024-08-16 | $0.3200 | 2024-09-20 |
| 2024-03-21 | $0.4700 | 2024-05-03 |
| 2023-08-10 | $0.2500 | 2023-09-15 |
No one on the platform has traded HKMPF yet.
| +0.00% |
| $5.2B |
| — |
| HLUBFH. Lundbeck A/S | $5.50 | +0.00% | $5.8B | — |
| LVZPFLivzon Pharmaceutical Group Inc. | $5.22 | +0.00% | $6.1B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 11.9× earnings vs its 20.0× historical median P/E.
Fair value ≈ $33.72 · price $20.11 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.